Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2021-08-25 Director's Dealing
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2021-08-25 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events that shareholders should know about. The text specifically announces the appointment of Dr. Christopher Kenney as Chief Medical Officer, effective August 23, 2021. There is no financial data, earnings information, or detailed report content. The document is primarily an announcement of a management change. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3102 characters, which is short and consistent with an announcement rather than a full report.
2021-08-23 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2021, reporting the announcement of financial results for the three and six month periods ended June 30, 2021. It states that the financial results were announced via a press release attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. The document length is 3420 characters, which is relatively short and consistent with an earnings release announcement rather than a full interim or annual report. Therefore, the appropriate classification is Earnings Release (ER).
2021-08-11 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-05 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-04 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.